Sobi用95万美元买下Arthrosi, 以便在晚期试验中获得有前途的古特药。 Sobi to buy Arthrosi for $950M to gain access to promising gout drug in late-stage trials.

Sobi同意购买私人生物技术Arthrosi治疗技术,预付9.5亿美元,可能支付5.5亿美元的潜在里程碑付款,以获得Pozdeutinnurad(AR882),这是目前两个第3阶段试验中的调查性口腔治疗。 Sobi has agreed to acquire private biotech Arthrosi Therapeutics for $950 million upfront, with up to $550 million in potential milestone payments, to gain access to pozdeutinurad (AR882), an investigational gout treatment currently in two Phase 3 trials. 该药物是一次日口服URAT1抑制剂,在降低尿酸水平和溶解硫化物方面已显示出可喜的成果,预计2026年将获得数据。 The drug, a once-daily oral URAT1 inhibitor, has shown promising results in lowering uric acid levels and dissolving tophi, with data expected in 2026. 这项收购有待监管批准,预计将于2026年初结束,将通过债务提供资金,目的是扩大索比河口的输油管,推动长期增长。 The acquisition, pending regulatory approval and expected to close in early 2026, will be funded through debt and aims to expand Sobi’s gout pipeline and drive long-term growth.